Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors

European Journal of Medicinal Chemistry

Volumn 84, Issue , 2014, Pages 444-453

  Calugi, Chiara ^a   Guarna, Antonio ^a   Trabocchi, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

AIDS; Amino acid; Drug design; Enzyme; Molecular docking; Small molecule

Indexed keywords

3 METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANOATE; 4 METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL] N PHENETHYLPENTANAMIDE; 4 METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANOIC ACID; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]HEXANOATE; METHYL 2 [ 7 [(1 HYDROXY 4 METHYLPENTAN 2 YL)CARBOMYL] 2 OXO 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL] 4 METHYLPENTANOATE; METHYL 3 ( 1 METHOXY 3 METHYL 1 OXOPENTAN 2 YL) 2 OXO 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 7 CARBOXYLATE; METHYL 3 METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANOATE; N BUTYL 4 METHYL 2 [ 2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANAMIDE; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MOLECULAR LIBRARY; PEPTIDOMIMETIC AGENT; 4 METHYL 2 (2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL N PHENETHYLPENTANAMIDE; 4 METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL] N PHENETHYLPENTANAMIDE; 4 METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANOIC ACID; 6,8 DIOXA 3 AZABICYCLO[3.2.1] OCTANE; ACETAL; ASPARTIC ACID; ASPARTIC PROTEINASE; METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]HEXANOATE; METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABIYCLO[3.2.1]OCTAN 3 YL]HEXANOATE; METHYL 2 [7 [(1 HYDROXY 4 METHYLPENTAN 2 YL)CARBAMOYL) 2 OXO 6,8 DIOXA 3 AZABICYCLO[3.2.1] OCTAN 3 YL] 4 METHYLPENTANOATE; METHYL 3 (1 METHOXY 3 METHYL 1 OXOPENTAN 2 YL) 2 OXO 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 7 CARBOXYLATE; METHYL 3 METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]OCTANE 7 CARBOXYLATE; METHYL 3 METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANOATE; N BUTYL 4 METHYL 2 [2 OXO 7 (PIPERIDINE 1 CARBONYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTAN 3 YL]PENTANAMIDE; OCTANE;

ARTICLE; DIELECTRIC CONSTANT; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SYNTHESIS; DRUG DESIGN; ENZYME INHIBITION ASSAY; IC50; MOLECULAR MODEL;

DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE; HIV PROTEASE INHIBITORS; MOLECULAR STRUCTURE; PEPTIDOMIMETICS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904572752     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.049     Document Type: Article

References (29)

1. L. Montagnier Historical essay. A history of HIV discovery Science 298 2002 1727 1728 (Pubitemid 35404104)
2. R.C. Gallo Historical essay. The early years of HIV/AIDS Science 298 2002 1728 1730 (Pubitemid 35404105)
3. WHO World Health Statistics 2012
4. N.E. Kohl, E.A. Emini, W.A. Schleif, L.J. Davis, J.C. Heimbach, R.A. Dixon, E.M. Scolnick, and I.S. Sigal Active human immunodeficiency protease is required for viral infectivity Proc. Natl. Acad. Sci. USA 85 1988 4686 4690
5. A. Wlodawer, and A. Gustchina Structural and biochemical studies of retroviral proteases Biochim. Biophys. Acta 1477 2000 16 34 (Pubitemid 30119889)
6. A. Mastrolorenzo, S. Rusconi, A. Scozzafava, G. Barbaro, and C.T. Supuran Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors Curr. Med. Chem. 14 2007 2734 2748 (Pubitemid 350130917)
7. A.M.J. Wensing, N.M. Van Maarseveen, and M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral. Res. 85 2010 59 74
8. D. Leung, G. Abbenante, and D.P. Fairlie Protease inhibitors: current status and future prospects J. Med. Chem. 43 2000 305 341 (Pubitemid 30102072)
9. J.P. Sommadossi HIV protease inhibitors: pharmacologic and metabolic distinctions AIDS 13 1999 S29 S40
10. C. Calugi, A. Guarna, and A. Trabocchi Heterocyclic HIV protease inhibitors Curr. Med. Chem. 20 2013 3693 3710
11. S.R. Turner, J.W. Strohbach, R.A. Tommasi, P.A. Aristoff, P.D. Johnson, H.I. Skulnick, L.A. Dolak, E.P. Seest, P.K. Tomich, M.J. Bohanon, M.M. Horng, J.C. Lynn, K.T. Chong, R.R. Hinshaw, K.D. Watenpaugh, M.N. Janakiraman, and S. Thaisrivongs Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class J. Med. Chem. 41 1998 3467 3476 (Pubitemid 28406555)
12. R. Rothenberg, M. Woeffel, R. Stoneburner, J. Milberg, R. Parker, and B. Truman Survival with the acquired immune deficiency syndrome N. Engl. J. Med. 31 1987 1297 1302
13. A. Schmidt-Westhausen, R.A. Schiller, H.D. Pohle, and P.A. Reichart Oral Candida and Enterobacteriaceae in HIV-1 infection: correlation with clinical candidiasis and antimycotic therapy J. Oral. Pathol. Med. 20 1991 467 472
14. A. Gruber, C. Speth, E. Lukasser-Vogl, R. Zangerle, M. Borg-von Zepelin, M.P. Dierich, and R. Würzner Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro Immunopharmacology 41 1999 227 234 (Pubitemid 29243825)
15. M. Borg von Zepelin, I. Meyer, R. Thomssen, R. Wurzner, D. Sanglard, A. Telenti, and M. Monod HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases J. Invest. Dermatol. 113 1999 747 751
16. A. Gruber, J. Berlit, C. Speth, C. Lass-Florl, G. Kofler, M. Nagl, M. Borg von Zepelin, M.P. Dierich, and R. Wurzner Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors Immunobiology 201 1999 133 144 (Pubitemid 29457306)
17. C. Calugi, A. Guarna, and A. Trabocchi Insight into the structural similarità between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors J. Enzyme Inhib. Med. Chem. 28 2013 936 943
18. H.C. Korting, M. Schaller, G. Eder, G. Hamm, U. Böhmer, and B. Hube Effects of the human immunodeficiency virus (HIV) protease inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteases of Candida albicans isolates from HIV-infected patients Antimicrobial. Agents. Chemother. 43 1999 2038 2042 (Pubitemid 29395205)
19. A. Cassone, F. De Bernardis, A. Torosantucci, E. Tacconelli, M. Tumbarello, and R. Cauda In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors J. Infect. Dis. 180 1999 448 453 (Pubitemid 30256327)
20. A. Trabocchi, C. Mannino, F. Machetti, F. De Bernardis, S. Arancia, R. Cauda, A. Cassone, and A. Guarna Identification of inhibitors of drug resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds J. Med. Chem. 53 2010 2502 2509
21. C. Calugi, A. Trabocchi, F. De Bernardis, S. Arancia, P. Navarra, R. Cauda, A. Cassone, and A. Guarna Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype Bioorg. Med. Chem. 20 2012 7206 7213
22. A. Guarna, A. Guidi, F. Machetti, G. Menchi, E.G. Occhiato, D. Scarpi, S. Sisi, and A. Trabocchi Synthesis and reactivity of bicycles derived from tartaric acid and - amino acids: a novel class of conformationally constrained dipeptide isosteres based upon Enantiopure 3-Aza-6,8-dioxabicyclo[3.2.1]octane- 7-carboxylic acid J. Org. Chem. 64 1999 7347 7364
23. A. Trabocchi, G. Menchi, F. Guarna, F. Machetti, D. Scarpi, and A. Guarna Design, synthesis, and applications of 3-Aza-6,8-Dioxa-Bicyclo[3.2.1]Octane- based scaffolds for peptidomimetic chemistry Synlett 2006 331 353 (Pubitemid 43288564)
24. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function J. Comput. Chem. 19 1998 1639 1662 (Pubitemid 128590223)
25. F. Mohamadi, N.G.J. Richards, W.C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W.C. Still MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics J. Comput. Chem. 11 1990 440 467
26. A. Gillet, M. Sanner, D. Stoffler, and A. Olson Tangible interfaces for structural molecular biology Structure 13 2005 483 491 (Pubitemid 40342887)
27. DeLano, W.L., The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA, USA. [ http://www.pymol.org ].
28. W.L. Jorgensen, and J. Tirado-Rives The OPLS force field for proteins. Energy minimizations for crystals of cyclic peptides and crambin J. Am. Chem. Soc. 110 1988 1657 1666
29. W.C. Still, A. Tempczyk, R.C. Hawley, and T. Hendrickson Semianalytical treatment of solvation for molecular mechanics and dynamics J. Am. Chem. Soc. 112 1990 6127 6129